title: [The Importance of teriparatide in the treatment of osteoporosis].
abstract: The anabolic agent teriparatide (TPTD) clearly increases bone mineral density both in daily and weekly formulations. In addition, the effectiveness of daily TPTD in reducing the risks of vertebral and non-vertebral fractures and of weekly TPTD in reducing the risk of vertebral fractures has been established. TPTD is indicated for severe osteoporosis, such as cases of multiple fractures, hip fractures, and fractures sustained during antiresorptive therapy. TPTD has also been shown to be effective for male osteoporosis and glucocorticoid-induced osteoporosis. Furthermore, TPTD can only be given for a limited duration, and requires sequential antiresorptive therapy following completion of administration. TPTD is the only anabolic agent that is currently available, and more effective methods of use such as combination and sequential therapies are being investigated. Moreover, clinical development of novel anabolic agents such as abaloparatide, a parathyroid hormone-related protein(PTHrP)analog, is being actively undertaken.
authors.affiliation: Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
authors.forename: Mika
authors.initials: M
authors.lastname: Yamauchi
mesh_terms: D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D019379:Teriparatide / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide